ENGLEWOOD, Colo., June 18, 2021 /PRNewswire/ – Ampio
Pharmaceuticals (NYSE American: AMPE), a clinical stage
biopharmaceutical company focused on the advancement of
immunology-based therapies for prevalent inflammatory conditions,
today announced that the Company is expected to join the small cap
Russell 2000® Index and the
broad-market Russell 3000® Index at the
conclusion of this year's reconstitution of the Russell stock
indexes, effective after the U.S. stock market opens on
Monday, June 28, 2021, accordingly to
a preliminary list of additions posted on June 4, 2021.
Michael Macaluso, the Company's
President and Chief Executive Officer, stated, "Inclusion in the
Russell Indexes is an important milestone and will increase the
overall awareness and exposure of our Company within the investment
Annual Russell indexes reconstitution captures the 4,000 largest
U.S. stocks as of May 7, 2021,
ranking them by total market capitalization. Membership in the U.S.
all-cap Russell 3000 Index, which remains in place for one year,
means automatic inclusion in the large-cap Russell
1000® Index or small-cap Russell
2000® Index as well as the appropriate
growth and value style indexes. FTSE Russell determines membership
for its Russell indexes primarily by objective
market-capitalization rankings and style attributes.
Russell U.S. Indexes are part of the FTSE Russell, a leading
global index provider, and are widely used by investment managers
and institutional investors as the basis for index funds and as
benchmarks for active investment strategies. FTSE Russell reports
approximately $10.6 trillion in
assets are benchmarked against Russell's U.S. indexes. For more
information on the Russell 3000® Index and
Russell 2000® Index and the Russell U.S.
Indexes reconstitution, visit the "Russell Reconstitution" section
at FTSE Russell website.
About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc. is a biopharmaceutical company
primarily focused on the advancement of immunology-based therapies
to treat prevalent inflammatory conditions for which there are
limited treatment options. Ampio's lead drug, Ampion™, is backed by
an extensive patent portfolio with intellectual property protection
extending through 2035 and will be eligible for 12-year FDA market
exclusivity upon approval as a novel biologic under the biologics
price competition and innovation act (BPCIA).
About FTSE Russell
FTSE Russell is a global index leader that provides innovative
benchmarking, analytics and data solutions for investors worldwide.
FTSE Russell calculates thousands of indexes that measure and
benchmark markets and asset classes in more than 70 countries,
covering 98% of the investable market globally.
FTSE Russell index expertise and products are used extensively
by institutional and retail investors globally. Approximately
$17.9 trillion is currently
benchmarked to FTSE Russell indexes. For over 30 years, leading
asset owners, asset managers, ETF providers and investment banks
have chosen FTSE Russell indexes to benchmark their investment
performance and create ETFs, structured products and index-based
A core set of universal principles guides FTSE Russell index
design and management: a transparent rules-based methodology is
informed by independent committees of leading market participants.
FTSE Russell is focused on applying the highest industry standards
in index design and governance and embraces the IOSCO Principles.
FTSE Russell is also focused on index innovation and customer
partnerships as it seeks to enhance the breadth, depth and reach of
FTSE Russell is wholly owned by London Stock Exchange Group.
For more information, visit www.ftserussell.com.
Forward Looking Statements
Ampio's statements in this press release that are not historical
fact, and that relate to future plans or events, are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by the use of words such as "believe,"
"expect," "plan," "anticipate," and similar expressions. These
forward-looking statements include statements regarding Ampio's
expectations with respect to Ampion and its classification, as well
as those associated with regulatory approvals and other FDA
decisions, the Biological License Application (BLA), the ability of
Ampio to enter into partnering arrangements, clinical
trials and decisions and changes in business conditions and similar
events, the ability to receive regulatory approval to conduct
clinical trials, that Ampion may be used to treat ARDS induced by
COVID-19, all of which are inherently subject to various risks and
uncertainties. The risks and uncertainties involved include those
detailed from time to time in Ampio's filings with the Securities
and Exchange Commission, including without limitation, under
Ampio's Annual Report on Form 10-K and other documents filed with
the Securities and Exchange Commission. Ampio undertakes no
obligation to revise or update these forward-looking statements,
whether as a result of new information, future events or
View original content to download
SOURCE Ampio Pharmaceuticals, Inc.